Valuation : Syntara Limited

Market Cap 51.01M 36.77M 31.64M 29.77M 27.19M 50.87M 3.47B 352M 137M 1.78B 138M 135M 5.74B P/E 2027 *
-5.2x
P/E 2028 * -8.67x
Enterprise Value 18.21M 13.13M 11.29M 10.63M 9.71M 18.16M 1.24B 126M 48.73M 636M 49.29M 48.21M 2.05B EV / Sales 2027 *
-
EV / Sales 2028 * 4.71x
Free-Float
72.62%
Yield 2027 *
-
Yield 2028 * -
1 month-10.34%
3 months+4.00%
6 months-18.75%
Current year-25.71%
1 week 0.02
Extreme 0.025
0.03
1 month 0.02
Extreme 0.024
0.04
Current year 0.02
Extreme 0.019
0.04
1 year 0.02
Extreme 0.019
0.04
3 years 0.01
Extreme 0.014
0.1
5 years 0.01
Extreme 0.014
0.15
10 years 0.01
Extreme 0.014
0.37
Manager TitleAgeSince
Chief Executive Officer 64 12/03/2013
Director of Finance/CFO - 31/08/2024
Chief Tech/Sci/R&D Officer - 01/07/2022
Director TitleAgeSince
Director/Board Member 64 12/03/2013
Chairman 68 03/10/2023
Director/Board Member - 16/12/2022
Date Insider Type Main position Quantity % Market Cap. Importance
13/03/25 Buy

Director

9,753,442 0.6008%
24/09/24 Buy

Director

53,571,429 4.1513%
12/08/21 Expiration

Chief Executive Officer

471,000 0.1040%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%+4.00%-35.00% 36.77M
-1.79%-2.27%+43.23%+88.96% 67.98B
-2.06%-0.18%+39.67%+86.44% 64.94B
-0.31%+6.54%-12.96%+378.92% 27.58B
+0.86%+1.65%-7.74%-14.95% 26.06B
-3.00%-2.90%+33.13%+12.54% 25.74B
-1.46%+0.42%+23.61%-18.61% 20.09B
-2.96%-15.21%+216.20%+368.10% 17.16B
-1.49%-4.88%-6.60%+531.89% 14.92B
-0.20%+8.37%+55.78%+164.98% 14.62B
Average -1.24%+0.23%+38.83%+156.33% 27.91B
Weighted average by Cap. -1.52%+0.18%+38.37%+137.33%

Financials

2027 *2028 *
Net sales - 5.5M 3.96M 3.41M 3.21M 2.93M 5.49M 374M 37.93M 14.72M 192M 14.89M 14.56M 619M
Net income -31.85M -22.96M -19.76M -18.59M -16.98M -31.76M -2.17B -220M -85.23M -1.11B -86.21M -84.33M -3.58B -31.5M -22.71M -19.54M -18.38M -16.79M -31.41M -2.14B -217M -84.29M -1.1B -85.26M -83.4M -3.54B
Net Debt -32.8M -23.64M -20.34M -19.14M -17.49M -32.71M -2.23B -226M -87.77M -1.15B -88.78M -86.85M -3.69B -25.1M -18.09M -15.57M -14.65M -13.38M -25.03M -1.71B -173M -67.17M -876M -67.94M -66.46M -2.82B
Logo Syntara Limited
Syntara Limited is an Australia-based clinical-stage drug development company. The Company is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The Company is also advancing topical pan-LOX inhibitors in scar revision, keloid scarring and scar prevention post-surgery. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.
Employees
-
Date Price Change Volume
04/09/26 A$0.0260 0.00% 272,031
03/09/26 A$0.0260 0.00% 414,042
02/09/26 A$0.0260 0.00% 859,687
01/09/26 A$0.0260 0.00% 254,039
31/08/26 A$0.0260 0.00% 2,184,770
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.0260AUD
Average target price
0.1050AUD
Spread / Average Target
+303.85%

Quarterly revenue - Rate of surprise